Vaxart, Inc. VXRT
We take great care to ensure that the data presented and summarized in this overview for Vaxart, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VXRT
View all-
Sio Capital Management, LLC New York, NY13.6MShares$8.3 Million6.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$6.15 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.97MShares$2.42 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.54MShares$1.55 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.77MShares$1.08 Million0.0% of portfolio
-
Silverarc Capital Management, LLC1MShares$610,0000.21% of portfolio
-
State Street Corp Boston, MA594KShares$362,4280.0% of portfolio
-
Northern Trust Corp Chicago, IL409KShares$249,6010.0% of portfolio
-
Squarepoint Ops LLC New York, NY265KShares$161,6550.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA260KShares$158,3310.0% of portfolio
Latest Institutional Activity in VXRT
Top Purchases
Top Sells
About VXRT
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Insider Transactions at VXRT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 18
2024
|
W. Mark Watson Director |
BUY
Open market or private purchase
|
Direct |
20,000
+20.38%
|
$0
$0.68 P/Share
|
|
Jun 12
2024
|
Phillip E Lee Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,007
-0.83%
|
$0
$0.76 P/Share
|
|
Jun 11
2024
|
Elaine J Heron Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+28.29%
|
-
|
|
Jun 11
2024
|
Michael J. Finney Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+2.28%
|
-
|
|
Jun 11
2024
|
David E. Wheadon Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+34.22%
|
-
|
|
Jun 11
2024
|
Robert A. Yedid Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+31.69%
|
-
|
|
Jun 11
2024
|
W. Mark Watson Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+21.59%
|
-
|
|
Mar 28
2024
|
Sean Tucker SVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,902
-1.09%
|
$3,902
$1.3 P/Share
|
|
Mar 28
2024
|
James F. Cummings Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,292
-1.0%
|
$3,292
$1.3 P/Share
|
|
Mar 18
2024
|
Phillip E Lee Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+27.12%
|
-
|
|
Mar 18
2024
|
Sean Tucker SVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+17.64%
|
-
|
|
Mar 18
2024
|
Edward B Berg SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+24.95%
|
-
|
|
Mar 18
2024
|
James F. Cummings Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+21.42%
|
-
|
|
Mar 18
2024
|
Steven Lo President, Chief Exec Officer |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+50.0%
|
-
|
|
Feb 02
2024
|
Sean Tucker SVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,220
-2.72%
|
$9,220
$1.2 P/Share
|
|
Feb 02
2024
|
Edward B Berg SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
9,220
-4.85%
|
$9,220
$1.2 P/Share
|
|
Feb 02
2024
|
James F. Cummings Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,965
-3.21%
|
$7,965
$1.2 P/Share
|
|
Dec 15
2023
|
Phillip E Lee Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,943
-3.77%
|
$0
$0.63 P/Share
|
|
Dec 08
2023
|
Phillip E Lee Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
35,151
-18.22%
|
$0
$0.71 P/Share
|
|
Dec 08
2023
|
Sean Tucker SVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
34,288
-9.18%
|
$0
$0.71 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 690K shares |
|---|---|
| Open market or private purchase | 20K shares |
| Payment of exercise price or tax liability | 176K shares |
|---|